多参数MRI扩散模型联合临床信息预测胰腺导管腺癌Ki-67表达的前瞻性队列研究
前瞻性队列纳入65例病理确诊胰腺导管腺癌患者,术前行3.0T MRI含IVIM与DKI序列并收集临床实验室数据,以免疫组化Ki-67 50%为截断值分组。高表达组单核细胞计数和DKI-MD更低、IVIM f值更高,三者联合模型AUC为0.913(95%CI 0.841-0.985),敏感度82.4%、特异度83.3%。
要点
- 以Ki-67 50%为界,48例(73.8%)低表达、17例(26.2%)高表达。
- 高表达组IVIM f值较低于表达组升高(14.08±3.41% vs 10.90±3.83%)。
- 高表达组DKI-MD较低于表达组降低(1.26±0.17 vs 1.65±0.17×10⁻³ mm²/s)。
核心结论
- 联合单核细胞计数、IVIM f值和DKI-MD的多参数模型对PDAC术前无创评估Ki-67表达状态具有优秀诊断性能,为精准医学实践和个体化治疗策略提供可靠工具。
研究设计与样本
- 前瞻性队列研究,纳入2024年1月至2025年5月65例组织病理学确诊的PDAC患者,均行3.0T MRI常规序列及先进扩散加权成像序列,手术或活检前一周内收集临床与实验室资料,以免疫组化染色Ki-67 50%为截断值,两名放射科医师独立定量测量(观察者间ICC>0.85),采用单因素及多因素logistic回归筛选独立预测因子,ROC曲线和DeLong检验评估诊断性能。
关键影像表现/征象
- 高Ki-67表达组IVIM f值高于低表达组(14.08±3.41% vs 10.90±3.83%,P=0.004)。
- 高Ki-67表达组DKI-MD低于低表达组(1.26±0.17 vs 1.65±0.17×10⁻³ mm²/s,P<0.001)。
诊断标准与关键数值
- 以免疫组化Ki-67表达50%为截断值,≥50%为高表达、<50%为低表达。
- 单核细胞计数单独预测Ki-67表达的AUC为0.763。
- IVIM f值单独预测的AUC为0.732。
- DKI-MD单独预测的AUC为0.800。
- 联合单核细胞计数、IVIM f值和DKI-MD的模型AUC为0.913(95%CI 0.841-0.985),敏感度82.4%、特异度83.3%,显著优于各单独模型(P<0.001)。
临床应用与阅片要点
- 阅片时可定量测量IVIM f值和DKI-MD,并结合术前单核细胞计数,用于无创预测PDAC的Ki-67表达状态。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the diagnostic value of intravoxel incoherent motion (IVIM) and diffusion kurtosis imaging (DKI) parameters combined with clinical information for predicting Ki-67 expression in pancreatic ductal adenocarcinoma (PDAC).
METHODS: This prospective cohort study enrolled 65 patients with histopathologically confirmed PDAC between January 2024 and May 2025. All patients underwent 3.0T MRI including conventional sequences and advanced diffusion-weighted imaging sequences. Clinical data and laboratory parameters were collected within one week before surgery or biopsy. Ki-67 expression was assessed using immunohistochemical staining with 50% as the cutoff value. Two radiologists independently performed quantitative measurements with excellent inter-observer reliability (ICC > 0.85). Univariate and multivariate logistic regression analyses identified independent predictors. ROC curve analysis and DeLong test evaluated diagnostic performance.
RESULTS: Based on Ki-67 expression threshold of 50%, 48 patients (73.8%) were classified as low expression and 17 patients (26.2%) as high expression. Compared to the low Ki-67 group, the high expression group demonstrated significantly lower monocyte count (0.35 ± 0.09 vs. 0.49 ± 0.16 × 10⁹/L, P = 0.001), higher IVIM f-value (14.08 ± 3.41% vs. 10.90 ± 3.83%, P = 0.004), and lower DKI-MD (1.26 ± 0.17 vs. 1.65 ± 0.17 × 10⁻³ mm²/s, P < 0.001). Individual prediction models achieved AUCs of 0.763 (monocyte count), 0.732 (IVIM f-value), and 0.800 (DKI-MD). The combined prediction model integrating these three parameters demonstrated excellent diagnostic performance with AUC of 0.913 (95% CI: 0.841-0.985), sensitivity of 82.4%, and specificity of 83.3%, significantly outperforming all individual models (P < 0.001).
CONCLUSION: This multi-parametric combined prediction model achieves excellent diagnostic performance for preoperative non-invasive assessment of Ki-67 expression status in PDAC, providing a reliable tool for precision medicine practice and personalized treatment strategies.
引用
- Li K, Li J, Liu X, et al. Multi-parametric MRI diffusion models combined with clinical information for predicting Ki-67 expression in pancreatic ductal adenocarcinoma: a prospective cohort study. Abdom Radiol (NY). 2025. PMID: 40879693. doi:10.1007/s00261-025-05164-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。